【摘要】 目的　通过对运用化疗联合中药治疗原发性肺癌的临床观察 ,探讨T细胞亚群和自然杀伤 (NK)细胞的变化及其在临床疗效评价和预后判断中的应用价值。方法　单用MVP化疗方案和化疗联合中药方案各治疗原发性肺癌患者 30例 ,观察治疗前后T细胞亚群、NK细胞等细胞免疫指标的变化 ,并于 1年后随访 ,了解疾病发展情况。结果　 1.治疗后化疗联合中药治疗组患者NK细胞和CD4 /CD8比值的提高稳定率分别为 90 .0 %和 86 .7% ,单纯化疗组则分别为 5 6 .7%和 6 3.3%。 2 .有效病例中 ,NK细胞和CD4 /CD8比值升高分别占96 .7%和 10 0 % ;稳定病例中 ,NK细胞和CD4 /CD8比值增高均占 94 .1%。 3.1年后随访结果显示 ,在NK细胞和CD4 /CD8比值增高的 4 6例患者中 ,病情稳定的占 89.1% ,恶化的占 10 .9% ;在死亡的 14例患者中 ,NK细胞和CD4 /CD8比值均显著降低。结论　T细胞亚群和NK细胞等指标可用于药物治疗肿瘤疾病的疗效评价和预后判断更多还原

【Abstract】 Objective To explore the clinical implication of T cell subgroup and natural killet (NK) cell in the therapeutic evaluation and prognosis judgment of pulmonary carcinoma. Methods 30 patients with pulmonary carcinoma were treated with MVP chemotherapy combining chinese medical therapy, compared with MVP chemotherapy only. The changes of T cell subgroup and NK cell before and after treatment were observed through one year follow up survey. Results 1. The elevated and stable rates of NK cell and CD4/CD8 were respectively 90% and 93.3% after combined therapy, 63.3% and 66.6% after single therapy. 2. In effective cases the elevated rates of NK cell and CD4/CD8 were respectively 96.7% and 100%. In stable cases the elevated rates of NK cell and CD4/CD8 both were 94.1% . 3. The result of one year follow up survery showed that 41 of 46 patients with increased NK cell and CD4/CD8 were steady state, and five patients were exacerbation. In 14 death cases, the levels of NK cell and CD4/CD8 were remarkably reduced. Conclusions The determination of T cell subgroups and NK cell is important in the therapeutic evaluation and prognosis judgments of pulmonary carcinoma.更多还原